@prefix nkg: . @prefix nt: . @prefix orcid: . @prefix bl: . @prefix this: . @prefix sub: . @prefix np: . @prefix rdf: . @prefix xsd: . @prefix rdfs: . @prefix prov: . @prefix npx: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubInfo; a np:Nanopublication . } sub:assertion { a bl:Disease . sub:association rdf:object ; rdf:predicate bl:treats; rdf:subject ; a rdf:Statement; rdfs:label "Clozapine is not recommended for OCD due to poor evidence of efficacy [170]. In addition, several case reports and clinical studies support the association of clozapine with worsening or onset of obsessive-compulsive symptoms in patients with a psychotic disorder [171-176]. At least 20% of individuals treated with clozapine (and other antiserotonergic antipsychotics) would experience worsening or emergence of obsessive-compulsive symptoms [177], which are dose-related [178] and generally reversible upon discontinuation of clozapine treatment and switch to a different antipsychotic [179]"; bl:has_population_context sub:context; bl:provided_by ; bl:publications ; bl:relation nkg:OffLabelIndication . sub:context a bl:Cohort; rdfs:label "adults" . a bl:Drug . } sub:provenance { sub:assertion prov:generatedAtTime "2021-08-25T14:52:29.045065"^^xsd:dateTime . } sub:pubInfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCamPJb4SzqpLXn//XJ5dlVfzz6QI+RPmiJTLXF/by2JR7sHMKRsCQDFsYMlq8zGHghOIkjRP9dpLZUtZzUcHt3MXiFKEPo8eGzUe9p+JXKFC8xxkJr94z2vq6IdMf71Iu1GH8SeDAKt/DgYO4zNaw8VuXvxnZRewKZSA+u8zWPVwIDAQAB"; npx:hasSignature "GsbY5Rbf6Gbvaiit2lQi84DcwIpIcxQg1AFco8HJT0BKmN2VqnPquPkYM9KgdePNBhe65iEH+k+zJjAeLnsqZdoNsCl55SrU56jJTiDFSld3kMbWYkyXoMrWYlLsyGSo8z9O9/MXAvNbpoRLYIsp+6P1gs2DqdM5mr/Q0Wf4ve8="; npx:hasSignatureTarget this: . this: prov:generatedAtTime "2021-08-25T14:52:29.045065"^^xsd:dateTime; prov:wasAttributedTo orcid:0000-0002-7641-6446; nt:wasCreatedFromTemplate . }